NUCLEIX
DEAD

Serial Number

97842013

Owner

Nucleix Limited

Attorney

Jennifer Sheehan Anderson

Filing Date

Mar 16, 2023

Add to watchlist:

No watchlists yet
View on USPTO

NUCLEIX Trademark

Serial Number: 97842013

NUCLEIX is a trademark filed by Nucleix Limited on March 16, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Nucleix Limited (5 trademarks)

Pekeris 3
Rehovot 7670203 , IL

Entity Type: 03

Trademark Details

Filing Date

March 16, 2023

Registration Date

Not Registered

Goods & Services

Diagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection or detection of or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; diagnostic reagents for medical purposes

Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use

Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing cancer screening services; providing screening services for chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease

Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 20, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 20, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 4, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 4, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 4, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Apr 7, 2023 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 6, 2023 NWOS
NEW APPLICATION ENTERED
Mar 20, 2023 NWAP